Reimbursement scheme Forxiga®

General information

TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF).

TBR Nederland started a TerugBetaalRegeling from 13 February 2023 for Forxiga® (dapagliflozin) 10 mg for heart failure patients with a LVEF ≥ 40% (HFmrEF & HFpEF), without diabetes type 2 and/or chronic kidney disease. The end date for this TBR for this patient group has not yet been determined.

The TerugBetaalRegeling applies for adults (>18y) with heart failure with a LVEF ≥40% (HFmrEF & HFpEF), with exceptions of patients who also have:

- Chronic kidney disease and/or;

- Diabetes mellitus type 2 who:

o Use metformin and/or SU or

o Previous experienced a cardiovascular event

NB: for the excluded group GVS reimbursement is already available. See the current GVS reimbursement in the ‘reimbursement overview’ and in the digital ‘reimbursement guide’.

For a complete reimbursement overview of Forxiga® (dapagliflozin) 10 mg, click here

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.

Dose	Forxiga® 10mg
Type	Tablets
Active ingredient	DAPAGLIFLOZINE

Reimbursement

Conditions

The full cost of Forxiga® (dapagliflozine) 10 mg is reimbursed through TBR Nederland.

Who can submit a claim

Patients or their caregiver can claim the Personal Contribution for Forxiga® (dapagliflozine) 10mg online or by mail.
Pharmacists can only claim this medicine online on behalf of the patient.

From when till when can you submit a claim

You can only send in your expense with an issue date from February 13, 2023. For the Reimbursement Scheme of this medicine no closing date has been determined yet.